X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
innovator infliximab (227) 227
double-blind (223) 223
parallel-group (199) 199
index medicus (192) 192
humans (157) 157
efficacy (146) 146
safety (143) 143
ct-p13 (132) 132
infliximab (121) 121
biosimilar pharmaceuticals - therapeutic use (105) 105
biosimilar (98) 98
crohns-disease (81) 81
gastroenterology & hepatology (78) 78
antibodies, monoclonal - therapeutic use (68) 68
inflammatory bowel disease (68) 68
rheumatoid-arthritis (63) 63
pharmacology & pharmacy (59) 59
ulcerative colitis (58) 58
infliximab - therapeutic use (56) 56
immunogenicity (53) 53
rheumatology (53) 53
ankylosing-spondylitis (52) 52
female (51) 51
male (51) 51
rheumatoid arthritis (51) 51
biosimilars (50) 50
crohn's disease (50) 50
monoclonal antibodies (50) 50
treatment outcome (50) 50
inflammatory bowel diseases - drug therapy (49) 49
inflammatory-bowel-disease (49) 49
biological products (45) 45
adult (44) 44
arthritis (43) 43
ulcerative-colitis (40) 40
middle aged (37) 37
pharmacokinetics (36) 36
multicenter (35) 35
gastrointestinal agents - therapeutic use (32) 32
active rheumatoid-arthritis (31) 31
immunology (31) 31
position statement (31) 31
antirheumatic agents - therapeutic use (30) 30
patients (29) 29
biosimilar pharmaceuticals - adverse effects (28) 28
therapy (28) 28
antibodies (27) 27
arthritis, rheumatoid - drug therapy (25) 25
clinical trials (25) 25
tumor necrosis factor-α (25) 25
maintenance therapy (24) 24
biosimilar pharmaceuticals (23) 23
crohn disease - drug therapy (23) 23
medicine, research & experimental (23) 23
prospective studies (23) 23
young adult (23) 23
adolescent (22) 22
colitis, ulcerative - drug therapy (21) 21
crohn’s disease (21) 21
extrapolation (21) 21
inflammatory bowel diseases (21) 21
methotrexate (21) 21
psoriasis (21) 21
rheumatoid factor (21) 21
ankylosing spondylitis (20) 20
anti-tnf (20) 20
biologics (20) 20
drug substitution (20) 20
oncology (20) 20
rheumatic diseases - drug therapy (20) 20
aged (19) 19
studies (19) 19
antibodies, monoclonal - adverse effects (18) 18
medicine, general & internal (18) 18
monoclonal-antibodies (18) 18
tumor necrosis factor-alpha - antagonists & inhibitors (18) 18
tumor necrosis factor-tnf (18) 18
animals (17) 17
biosimilar pharmaceuticals - economics (17) 17
care and treatment (17) 17
biosimilar pharmaceuticals - administration & dosage (16) 16
switch (16) 16
united states (16) 16
biotechnology & applied microbiology (15) 15
drug approval (15) 15
drugs (15) 15
interchangeability (15) 15
originator infliximab (15) 15
usage (15) 15
abridged index medicus (14) 14
clinical-outcomes (14) 14
crohns disease (14) 14
ecco position statement (14) 14
europe (14) 14
fda approval (14) 14
immunoglobulins (14) 14
medicine & public health (14) 14
pharmaceutical industry (14) 14
pharmacology (14) 14
remission induction (14) 14
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Internal Medicine, ISSN 0954-6820, 06/2019, Volume 285, Issue 6, pp. 653 - 669
Journal Article
Lancet, The, ISSN 0140-6736, 2017, Volume 389, Issue 10086, pp. 2304 - 2316
Journal Article
Therapeutic drug monitoring, ISSN 0163-4356, 12/2018, Volume 40, Issue 6, pp. 749 - 753
Background: SB2, an infliximab (IFX) biosimilar to the reference infliximab (R.I.) product (Remicade), received approval in the European Union for all IFX... 
SB2 | MULTICENTER | infliximab biosimilar | INNOVATOR INFLIXIMAB | EFFICACY | SAFETY | anti-TNF alpha | Flixabi | PLACE | PARALLEL-GROUP | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TOXICOLOGY | MEDICAL LABORATORY TECHNOLOGY | CT-P13 | Immunoassay | Biosimilar Pharmaceuticals - blood | Drug Monitoring - methods | Infliximab - blood | Humans | Evaluation | Infliximab | Analysis | Methods | Drug utilization
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 01/2017, Volume 76, Issue 1, pp. 58 - 64
Journal Article
Inflammatory Bowel Diseases, ISSN 1078-0998, 02/2017, Volume 23, Issue 2, pp. 233 - 243
Journal Article
Journal Article
Advances in Therapy, ISSN 0741-238X, 8/2015, Volume 32, Issue 8, pp. 742 - 756
Inflammatory autoimmune diseases (rheumatoid arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis) have a... 
Remicade | Psoriasis | Rheumatology | Internal Medicine | Oncology | Remsima | Biosimilar | Psoriatic arthritis | Medicine & Public Health | Infliximab | Rheumatoid arthritis | Cardiology | Pharmacology/Toxicology | Endocrinology | Ankylosing spondylitis | Crohn’s disease | Ulcerative colitis | MEDICINE, RESEARCH & EXPERIMENTAL | Remicade (R) | COST-EFFECTIVENESS | INNOVATOR INFLIXIMAB | CROHNS-DISEASE | ACTIVE RHEUMATOID-ARTHRITIS | Crohn's disease | ANKYLOSING-SPONDYLITIS | PSORIATIC-ARTHRITIS | PARALLEL-GROUP | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | Remsima (R) | QUALITY-OF-LIFE | NECROSIS-FACTOR INHIBITORS | Arthritis, Psoriatic - economics | Models, Econometric | Biosimilar Pharmaceuticals - therapeutic use | Europe | Humans | Spondylitis, Ankylosing - drug therapy | Infliximab - economics | Antibodies, Monoclonal - therapeutic use | Male | Biosimilar Pharmaceuticals - economics | Infliximab - therapeutic use | Spondylitis, Ankylosing - economics | Drug Costs - statistics & numerical data | Arthritis, Rheumatoid - drug therapy | Arthritis, Psoriatic - drug therapy | Antirheumatic Agents - economics | Female | Aged | Antibodies, Monoclonal - economics | Arthritis, Rheumatoid - economics | Cost Savings - statistics & numerical data | Prescription Fees - statistics & numerical data | Cost Savings - methods | Antirheumatic Agents - therapeutic use | Rheumatoid factor | Care and treatment | Analysis | Resveratrol | Budget | Autoimmune diseases | Original Research
Journal Article
Respiratory Medicine, ISSN 0954-6111, 05/2018, Volume 138, pp. S7 - S13
Infliximab, a monoclonal antibody against tumor necrosis factor alpha (TNF-α) is effective third-line therapy in severe sarcoidosis. The originator product of... 
PET-scan | Inflectra | Sarcoidosis | TNF-α inhibitor | Biosimilar | RHEUMATOID-ARTHRITIS | EXTRAPULMONARY SARCOIDOSIS | CARDIAC & CARDIOVASCULAR SYSTEMS | INNOVATOR INFLIXIMAB | METHOTREXATE | RANDOMIZED-TRIAL | F-18-FDG PET | THERAPY | RESPIRATORY SYSTEM | PARALLEL-GROUP | DOUBLE-BLIND | PULMONARY SARCOIDOSIS | Inflectra (R) | TNF-alpha inhibitor | Sarcoidosis, Pulmonary - drug therapy | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Positron-Emission Tomography | Infliximab - therapeutic use | Infection - epidemiology | Peptidyl-Dipeptidase A - blood | Sarcoidosis, Pulmonary - physiopathology | Adult | Female | Retrospective Studies | Radiopharmaceuticals | Antirheumatic Agents - therapeutic use | Severity of Illness Index | Biosimilar Pharmaceuticals - therapeutic use | Receptors, Interleukin-2 - blood | Treatment Outcome | Vital Capacity | Sarcoidosis, Pulmonary - blood | Sarcoidosis, Pulmonary - diagnostic imaging | Quality of Life | Fluorodeoxyglucose F18 | Respiratory Function Tests | Health Status | Antibodies, Neutralizing - blood | Cohort Studies | Therapy | Cardiac arrhythmia | Substance abuse treatment | Respiratory function | Interleukin | Nervous system | Recruitment | Infusion | Pain | Interleukin 2 | Infliximab | Peptidyl-dipeptidase A | Tomography | Carbon monoxide | Product safety | Drug dosages | Data analysis | Lymphatic system | Cytokines | Lung diseases | Positron emission | Fluorine isotopes | Tumor necrosis factor-α | Patients | Quality of life | Studies | Ethnicity | Rheumatoid arthritis | Angiotensin | Pulmonary functions | Monoclonal antibodies | Data collection | Positron emission tomography
Journal Article
Journal Article